Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 373
Filter
1.
A new standard of care for leiomyosarcoma.
Sidaway, Peter.
Nat Rev Clin Oncol ; 2024 Sep 19.
Article in English | MEDLINE | ID: mdl-39300213
2.
Tisotumab vedotin effective in recurrent cervical cancer.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(10): 703, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39039198

Subject(s)
Neoplasm Recurrence, Local , Uterine Cervical Neoplasms , Humans , Uterine Cervical Neoplasms/drug therapy , Female , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/pathology , Antibodies, Monoclonal, Humanized/therapeutic use
3.
Addition of sintilimab to standard therapy improves event-free survival.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(9): 640, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38886613

Subject(s)
Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols , Humans , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Progression-Free Survival
4.
Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(8): 566, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38877176

Subject(s)
Ipilimumab , Neoadjuvant Therapy , Nivolumab , Humans , Nivolumab/therapeutic use , Ipilimumab/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Melanoma/drug therapy , Chemotherapy, Adjuvant , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Agents, Immunological/adverse effects
5.
Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(8): 566, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38886612

Subject(s)
Acrylamides , Aniline Compounds , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Aniline Compounds/therapeutic use , Acrylamides/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Neoplasm Staging , Antineoplastic Agents/therapeutic use , Maintenance Chemotherapy/methods , Piperazines/therapeutic use , Treatment Outcome , Indoles , Pyrimidines
6.
Ponatinib superior to imatinib in Ph+ ALL.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(7): 483, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38806653

Subject(s)
Imatinib Mesylate , Imidazoles , Pyridazines , Humans , Pyridazines/therapeutic use , Pyridazines/adverse effects , Imatinib Mesylate/therapeutic use , Imidazoles/therapeutic use , Imidazoles/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/adverse effects , Protein Kinase Inhibitors/therapeutic use , Protein Kinase Inhibitors/adverse effects , Philadelphia Chromosome , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
7.
Adjuvant pembrolizumab improves overall survival in patients with RCC.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(7): 484, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38684928

Subject(s)
Antibodies, Monoclonal, Humanized , Carcinoma, Renal Cell , Kidney Neoplasms , Humans , Antibodies, Monoclonal, Humanized/therapeutic use , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/mortality , Kidney Neoplasms/drug therapy , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Chemotherapy, Adjuvant , Antineoplastic Agents, Immunological/therapeutic use
8.
Afami-cel provides a novel treatment option for rare sarcoma subtypes.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(6): 401, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38637649
9.
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(6): 402, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38565936

Subject(s)
Antibodies, Monoclonal, Humanized , Chemoradiotherapy , Uterine Cervical Neoplasms , Humans , Uterine Cervical Neoplasms/therapy , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/pathology , Female , Chemoradiotherapy/methods , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Treatment Outcome
10.
Laparoscopic hemihepatectomy is safe and effective.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(7): 484, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38684929

Subject(s)
Hepatectomy , Laparoscopy , Liver Neoplasms , Humans , Hepatectomy/methods , Laparoscopy/methods , Laparoscopy/adverse effects , Liver Neoplasms/surgery , Treatment Outcome
11.
A new standard of care for advanced-stage urothelial carcinoma.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(5): 336, 2024 May.
Article in English | MEDLINE | ID: mdl-38509334

Subject(s)
Carcinoma, Transitional Cell , Standard of Care , Humans , Carcinoma, Transitional Cell/pathology , Carcinoma, Transitional Cell/therapy , Carcinoma, Transitional Cell/drug therapy , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/therapy , Urinary Bladder Neoplasms/drug therapy , Neoplasm Staging , Urologic Neoplasms/pathology , Urologic Neoplasms/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
12.
Pegargiminase improves outcomes in nonepithelioid MPM.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(5): 336, 2024 May.
Article in English | MEDLINE | ID: mdl-38438632

Subject(s)
Polyethylene Glycols , Humans , Polyethylene Glycols/therapeutic use , Treatment Outcome , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/pathology
13.
Adjuvant sintilimab effective in high-risk HCC.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(3): 168, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38316989

Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Humans , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use
14.
KN046 shows tolerability and activity in TNBC.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(4): 251, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38365954

Subject(s)
Antineoplastic Agents , Triple Negative Breast Neoplasms , Humans , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/genetics , Antineoplastic Agents/adverse effects , Cell Line, Tumor , Cell Proliferation
15.
Repotrectinib effective in ROS1-fusion-positive NSCLC.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(3): 167, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38278875

Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Macrocyclic Compounds , Pyrazoles , Humans , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics
16.
From ESMO 2023: advances in lung cancer.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(1): 4, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37923903

Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics
17.
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(2): 83, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38082106

Subject(s)
Brain Neoplasms , Glioma , Humans , Proto-Oncogene Proteins B-raf/genetics , Glioma/drug therapy , Glioma/genetics , Brain Neoplasms/drug therapy , Brain Neoplasms/genetics , Mutation
18.
Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer.
Sidaway, Peter.
Nat Rev Clin Oncol ; 21(2): 83, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38114788

Subject(s)
Immunoconjugates , Maytansine , Ovarian Neoplasms , Humans , Female , Carcinoma, Ovarian Epithelial/drug therapy , Antibodies, Monoclonal, Humanized/adverse effects , Maytansine/therapeutic use , Immunoconjugates/therapeutic use , Ovarian Neoplasms/drug therapy , Drug Resistance, Neoplasm
19.
Sacituzumab govitecan improves OS in heavily pretreated patients.
Sidaway, Peter.
Nat Rev Clin Oncol ; 20(11): 734, 2023 11.
Article in English | MEDLINE | ID: mdl-37684406

Subject(s)
Immunoconjugates , Triple Negative Breast Neoplasms , Humans , Camptothecin/adverse effects , Immunoconjugates/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use
20.
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC.
Sidaway, Peter.
Nat Rev Clin Oncol ; 20(12): 817, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37749383

Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Antibodies, Monoclonal, Humanized/therapeutic use , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , ErbB Receptors/genetics
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL